Abstract
RNA interference (RNAi) provides the means for alternative antiviral therapy. Delivery of RNAi in the form of short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA) have demonstrated efficacy in gene silencing for therapeutic applications against viral diseases. Bioinformatics has played an important role in the design of efficient RNAi sequences targeting various pathogenic viruses. However, stability and delivery of RNAi molecules have presented serious obstacles for reaching therapeutic efficacy. For this reason, RNA modifications and formulation of nanoparticles have proven useful for non-viral delivery of RNAi molecules. On the other hand, utilization of viral vectors and particularly self-replicating RNA virus vectors can be considered as an attractive alternative. In this review, examples of antiviral therapy applying RNAi-based approaches in various animal models will be described. Due to the current coronavirus pandemic, a special emphasis will be dedicated to targeting Coronavirus Disease-19 (COVID-19).
Keywords:
RNA interference; shRNA; siRNA; miRNA; gene silencing; viral vectors; RNA replicons; COVID-19 1. Introduction
Since idoxuridine, the first anti-herpesvirus antiviral drug, reached the market in 1963 more than one hundred antiviral drugs have been formally approved [1]. Despite that, there is a serious need for development of novel, more efficient antiviral therapies, including drugs and vaccines, which has become even more evident all around the world today due to the recent coronavirus pandemic [2]. In this context, many drugs have been subjected to repurposing such as remdesivir, originally developed for Ebola virus disease (EVD) [3], hydroxychloroquine used for treatment of malaria [4] and lopinavir/ritonavir applied for HIV/AIDS therapy and prevention [5]. Unfortunately, follow-up studies have provided discouraging findings in many cases for instance, showing no benefit of hydroxychloroquine treatment of Coronavirus Disease.19 (COVID-19) patients [6]. Furthermore, very recently in search for alternative approaches, expression of 26 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) proteins in human cells identified 332 human proteins showing protein–protein interaction by affinity-purification mass spectrometry [7]. Further analysis identified 66 druggable human proteins or host factors, which were targeted by preclinical compounds, drugs in clinical trials or FDA-approved drugs. When a subset was screened in multiple viral assays, two sets of pharmacological agents with antiviral activity were identified, which could support therapeutic interventions of COVID-19.
Alternative strategies for antiviral drugs are naturally addressed currently including 5-substituted 2′-deoxyuridine analogues, nucleoside and pyrophosphate analogues, reverse transcriptase inhibitors, protease and integrase inhibitors, entry inhibitors, acyclic guanosine and nucleoside phosphonate analogues, immunostimulators, interferons and antimitotic inhibitors [1]. One approach that has received attention recently is the application of RNA interference (RNAi) for viral diseases. In this review are described the mechanisms behind RNAi and gene silencing and how these can potentially be implemented as therapeutic interventions to prevent viral replication and act as antiviral drugs. Examples of virus-based gene silencing in animal models are presented. Due to the current COVID-19 pandemic, a special emphasis is given to the application of gene silencing for prevention of coronavirus replication as a means for antiviral therapy.
2. RNAi and Gene Silencing
RNA-based gene silencing was originally discovered in plants and Caenorabditis elegans [8]. More recently, gene silencing was confirmed to occur in other organisms [9,10] and more than 6000 micro-RNA (miRNA) sequences have been identified in prokaryotes and eukaryotes [11] with more than 1000 of human origin [12,13]. The mechanism of gene silencing can occur either through mRNA degradation or suppression of translation. In the case of small interfering RNA (siRNA), the multiprotein component RNA induced silencing complex (RISC) binds the double-stranded siRNA, the siRNA strands are separated and the antisense single-stranded siRNA guides RISC to the target mRNA for degradation [14]. In addition to siRNAs, short hairpin RNAs (shRNAs) consist of two complementary 19–22 bp RNA sequences linked by a short loop of 4–11 nucleotides similar to the hairpin naturally present in miRNAs [15]. Delivery of shRNAs can take place by plasmid DNA or viral vectors, and followed by transcription, shRNAs are recognized by the endogenous enzyme Dicer in the cytoplasm, which then processes the shRNAs into siRNAs for binding to target mRNA leading to specific mRNA degradation [16]. Gene silencing is accomplished by miRNAs either through mRNA degradation or suppression of translation [17]. The mechanism of action comprises of transcription of chromosomal miRNA sequences in the nucleus, which are processed to primary miRNAs (pri-miRNAs) by RNAse III endonuclease Drosha and dsRNA-binding protein Pasha, generating the 60–70 nucleotide stem loop precursor miRNA (pre-miRNA). The pre-miRNA is cleaved by the RNase III endonuclease Dicer in the cytoplasm into a 22 nucleotide long ds-miRNA, which then can induce gene silencing. In the case of mRNA degradation, a similar mechanism to siRNA-guided RISC-targeting takes place for miRNAs. In contrast, translation suppression occurs when miRNAs bind to the untranslated region of the mRNA mediated by the RISC. An interesting alternative approach has been to target unusual miRNAs such as miR-451, which are Dicer-independent and instead are processed by the Argonaute 2 (Ago2) enzyme [18]. This approach has allowed therapeutic applications of both non-viral- and viral-based delivery, as described below.
In comparison to small-molecule or antibody-based drugs, the major advantage of RNAi-based strategies relates to the specific targeting of the drug function to a specific nucleotide sequence [19]. In this context, while small molecule inhibitors generally affect several targets, RNAi can provide highly specific action on unique targets [20]. Whole-genome sequencing and the establishment of comprehensive databases can further expand the potential range for RNAi-based drug discovery [21,22]. However, immune escape and stop codon mutations have been observed in patients with chronic hepatitis B virus (HBV) infections [23], which can be problematic for targeting specific sequences. Moreover, the same problem has been encountered for HIV, leading to the development of anti-escape strategies such as multiplexing, where a large number of shRNA-miRs were expressed using minimal flanking sequences from multiple endogenous miRNAs [24].
3. RNAi and Bioinformatics
Bioinformatics plays an important role in supporting RNAi-based antiviral therapy. For instance, a stochastic computational model has been designed to aid the development of anti-HIV RNAi therapies [25]. The model simulates the propagation of HIV infection in cells expressing RNAi, displaying targeting of multiple locations in the HIV genome. It also suggests that targeting the HIV transactivating response region (TAR) can be highly successful with a correctly selected RNAi target sequence. The model demonstrates the importance of efficient RNAi delivery systems to avoid leaving reservoirs of cells, where virus can propagate and mutate. Moreover, databases for design and algorithm predictions have been developed for siRNAs [26]. For instance, the viral siRNA database provides detailed siRNA information on 42 human viruses about siRNA sequences, target virus, genes, cell lines and assays as well as siRNA analysis tools such as siTarAlign for the alignment of siRNA and genome sequences of representative viruses [27,28]. Related to HIV, databases provide information on experimentally tested siRNA/shRNA sequences [29], escape mutations and nucleotide mismatches [30] and siRNA efficacy [31]. The design of siRNAs has also been based on analysis of nucleotide frequency at multiple locations in siRNAs [32] and the selection of effective siRNAs directed against conserved regions of HIV, hepatitis C (HCV), influenza virus and SARS-CoV [33]. The Viral siRNA Predictor was developed based on published data using features such as nucleotide frequency, thermodynamic factors and nucleotide location for prediction of siRNA targeting of pathogenic viruses [34]. However, the RNA structure might impose restrictions for RNA therapy based on properties of the HCV genome from primary sequence to tertiary structure [35].
4. Delivery of RNAi
As with all therapeutic approaches, delivery plays an essential role also for RNAi-based drugs, which has also been reviewed previously [36]. In this context, RNA has always been considered more problematic due its sensitivity to degradation. Moreover, cellular uptake presents another challenge as the cell membrane consists of a negatively charged bilayer of phospholipids and functional proteins, which negatively charged RNAi molecules cannot passively penetrate [19]. For this reason, extensive engineering of lipids and cell-penetrating peptides has enhanced RNA delivery. For instance, liposome-siRNA complexes have been demonstrated to promote transmembrane delivery of RNA [37]. Furthermore, cell-penetrating peptides such as chitosan can increase siRNA uptake and improve its gene silencing effect [38]. It has also been demonstrated that extracellular vesicles can be employed for efficient delivery of cholesterol-conjugated siRNA molecules [39]. Additionally, aptamer-modified extracellular vesicles facilitated tumor targeting of miRNA in tumor-bearing mice [40]. In another approach, aptamer surface labeling of nanoparticles showed selective siRNA delivery to metastatic breast cancer cells [41]. It has also been demonstrated that cholesterol modification resulted in uptake of siRNAs by dendritic cells (DCs) in vitro and in vivo [42].
An alternative delivery approach comprises the use of viral vectors. In this context, for instance adenovirus (Ad) [43], adeno-associated virus (AAV) [44] and retrovirus [45] vectors have been applied for gene silencing. Moreover, conditionally replicating lentivirus vectors have been engineered for the expression of siRNA and shRNA sequences [46]. Self-replicating rhabdoviruses [47] and alphaviruses [48] have also been applied for RNAi-based gene silencing. Moreover, it has been proposed that self-replicating RNA viruses could be used as delivery vehicles for small RNAs to induce long-term transcriptional gene silencing (TGS) for therapeutic interventions of various diseases [49]. In this context, cytoplasmic alphaviruses, flaviviruses and Sendai virus (SeV), as well as nucleoplasmic influenza A virus (IAV) and Borna disease viruses (BoDVs) are potential candidates for TGS.
7. Conclusions
In summary, RNAi-based gene silencing has presented great promise on several levels. Basic research has gained immensely as RNAi has together with proteomics become the most dynamic field of biotechnology [91]. RNAi has also played a prominent role in modern drug screening [92]. The emphasis in this review has been on antiviral therapeutic applications of RNAi, especially highlighting the application of viral vectors for the delivery of siRNAs, shRNAs and miRNAs. The majority of RNAi approaches so far has utilized non-viral delivery methods, which initially suffered from major problems related to RNA delivery and stability [93]. Numerous strategies, including modifications of the 5′ 7-methylguanosine triphosphate (m7 G) Cap structure, the poly (A) tail, 5′ and 3′ end untranslated regions and chemically modified nucleosides have improved the stability of synthetic mRNA molecules [94]. Another approach for improved mRNA delivery comprises the formulation of various nanoparticles based on liposomes, polymers and hybrid lipid polymers, which has provided protection against degradation, enhanced cellular delivery and extended duration of expression in vivo [95]. Although these modifications have improved the delivery of non-viral vectors, the features of superior delivery through highly efficient cell infection and the unmatched expression levels have made the application of viral vectors attractive for RNAi therapy. Viral vectors do not only deliver the RNAi drug, they actually manufacture the drug in the host target cell. Moreover, self-replicating RNA viruses provide extensive RNA amplification directly in the cytoplasm, generating enhanced gene silencing efficacy [96]. Moreover, self-replicating RNA virus vectors can be delivered as naked or encapsulated RNA and DNA plasmids due to their RNA amplification at significantly lower concentrations than synthetic mRNAs or conventional DNA plasmids. However, safety aspects related to the use of viral vectors should not be neglected, and for most viral vector expression systems, vector engineering and appropriate development guarantee safe use in humans. Today, several studies have confirmed the feasibility of RNAi-based gene silencing and inhibition of replication of pathogenic viruses by viral vectors in various animal models (Table 1). Despite recent progress in viral vector delivery, far more studies have been carried out with naked RNAi molecules, DNA-based vectors or liposome/polymer-based nanoparticles (Table 2). It needs to be reminded that translation of the basic concepts of RNAi have faced some limitations and hurdles, which include off-target effects of siRNAs, where ectopically applied siRNAs can alter the expression profiles of several non-targeted transcripts [97]. Moreover, miRNAs can affect down-regulation of target proteins, which in turn can inhibit protein translation and trigger non-specific degradation [98]. Another issue relates to the lethality due to acute liver failure observed in mice after tail vein injection of AAV-based shRNA delivery, which has required to carefully control the levels of ectopic expression of therapeutic shRNAs, as these can be processed into siRNAs eliciting off-target effects and competition with endogenous miRNAs for the RNAi machinery [99]. Another concern comprises the triggering of type I interferon production via activation of Toll-like receptors (TLRs) by certain sequence motifs in siRNAs, which can compromise the RNAi inhibitory effects [100]. This issue has been addressed by including at least one 2’-O-methyl (2’-OMe) in the sense or antisense strand of the siRNA [101].
The current COVID-19 pandemic has also demanded the exploration of all possible alternatives for the discovery of novel or repurposed antiviral drugs for SARS-CoV-2 including RNAi. Finally, it is appropriate to briefly summarize the status of RNAi-based drugs, although they represent other disease indications than viral infections. In this context, RNAi-based treatment of neovascular age-related macular degeneration (Sirna-027) showed a good safety profile in 26 patients in a phase I study [102], but the development was halted when the drug failed to meet a key efficiency endpoint in a phase II clinical trial [103]. Despite this setback and other challenges involving safety and potency, a new era of RNAi-based therapeutics was marked by the FDA approval of the first RNAi-based drug in August 2018 [104]. The drug ONPATTRO™ (patisiran) has also been approved by the European Commission for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults [105]. Although RNAi-based antiviral drugs are still some way off, patisiran may serve as an encouragement for the development of novel and efficient RNAi-based drugs for the treatment of infectious diseases.
Funding
This research received no external funding.
Conflicts of Interest
The author declares no conflict of interest.
References
- De Clercq, E.; Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016, 29, 695–747. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lundstrom, K. Coronavirus pandemic—Therapy and vaccines. Biomedicines 2020, 8, 109. [Google Scholar] [CrossRef] [Scilit]
- Warren, T.K.; Jordan, R.; Lo, M.K.; Ray, A.S.; Mackman, R.L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H.C.; et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016, 531, 381–385. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ben-Zvi, I.; Kivity, S.; Langevitz, P.; Schoenfeld, Y. Hydroxychloroquine: From malaria to autoimmunity. Clin. Rev. Allergy Immunol. 2012, 42, 145–153. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chandwani, A.; Shuter, J. Lopinavir/ritonavir in the treatment of HIV-infection: A review. Ther. Clin. Risk Manag. 2008, 4, 1023–1033. [Google Scholar] [PubMed]
- Das, S.; Bhowmick, S.; Tiwari, S.; Sen, S. An updated systematic review of the therapeutic role of hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Clin. Drug Investig. 2020, 40, 591–601. [Google Scholar] [CrossRef] [Scilit]
- Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; et al. A SARS-CoV-2 protein interaction map reveals target for drug repurposing. Nature 2020. [Google Scholar] [CrossRef] [Scilit]
- Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complimentary to lin-14. Cell 1993, 75, 843–854. [Google Scholar] [CrossRef] [Scilit]
- Pasquinelli, A.E.; Reinhart, B.J.; Slack, F.; Martindale, M.Q.; Kuroda, M.I.; Maller, B.; Hayward, D.C.; Ball, E.E.; Degnan, B.; Müller, P.; et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408, 86–89. [Google Scholar] [CrossRef] [Scilit]
- Lee, R.C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294, 862–864. [Google Scholar] [CrossRef] [Scilit]
- Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34, D140–D144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Krek, A.; Grun, D.; Poy, M.N.; Wolf, R.; Rosenberg, L.; Epstein, E.J.; MacMenamin, P.; da Piedade, I.; Gunsalus, K.C.; Stoffel, M.; et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37, 495–500. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRbase: From miRNA sequences to function. Nucleic Acids Res. 2019, 47, D155–D162. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dana, H.; Chalbatani, G.M.; Mahmoodzadeh, H.; Karimloo, R.; Rezaiean, O.; Moradzhadeh, A.; Mehmandoost, N.; Moazzen, F.; Mazraeh, A.; Marmari, V.; et al. Molecular mechanisms and biological functions of siRNA. Int. J. Biomed. Sci. 2017, 13, 48–57. [Google Scholar] [PubMed]
- Moore, C.B.; Guthrie, E.H.; Huang, T.-Z.; Taxman, D.J. Short hairpin RNA (shRNA): Design, delivery and assessment of gene knockdown. Methods Mol. Biol. 2010, 629, 141–158. [Google Scholar] [PubMed]
- Kutter, C.; Svoboda, P. miRNA, siRNA, piRNA: Knowns of the unknown. RNA Biol. 2008, 5, 181–188. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pillai, R. MicroRNA functions: Multiple mechanisms for a tiny RNA. RNA J. 2005, 11, 1753–1756. [Google Scholar] [CrossRef] [Scilit]
- Herrea-Carrillo, E.; Berkhout, B. Dicer-independent processing of small RNA duplexes: Mechanistic insights and applications. Nucl. Acids Res. 2017, 45, 10369–10379. [Google Scholar] [CrossRef] [Scilit]
- Chen, X.; Mangala, L.S.; Rodriguez-Aguayo, C.; Kong, X.; Lopez-Berestein, G.; Sood, A.K. RNA interference-based therapy and delivery systems. Cancer Metastasis Rev. 2018, 37, 107–124. [Google Scholar] [CrossRef] [Scilit]
- Arkin, M.R.; Tang, Y.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality. Chem. Biol. 2014, 21, 1102–1114. [Google Scholar] [CrossRef] [Scilit]
- Mohr, S.E.; Perrimon, N. RNAi screening: New approaches, understandings, and organisms. Wiley Interdiscip. Rev. RNA 2012, 3, 145–158. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rupaimoole, R.; Han, H.D.; Lopez-Berestein, G.; Sood, A.K. MicroRNA therapeutics: Principles, expectations, and challenges. Chin. J. Cancer 2011, 30, 368–370. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Colagrossi, L.; Hermans, L.E.; Salpini, R.; Di Carlo, D.; Pas, S.D.; Alvarez, M.; Ben-Ari, Z.; Boland, G.; Bruzzone, B.; Coppola, N.; et al. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect. Dis. 2018, 18, 251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Choi, J.-G.; Bharaj, P.; Abraham, S.; Ma, H.; Yi, G.; Ye, C.; Dang, Y.; Manjunath, N.; Wu, H.; Shankar, P. Multiplexing seven miRNA-Based shRNAs to suppress HIV replication. Mol. Ther. 2015, 23, 310–320. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Leonard, J.N.; Schaffer, D.V. Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. J. Virol. 2005, 79, 1645–1654. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Quereshi, A.; Tantray, V.G.; Kirmani, A.R.; Ahangar, A.G. A review on current status on antiviral siRNA. Rev. Med. Virol. 2018, 28, e1976. [Google Scholar] [CrossRef] [Scilit]
- VIRsiRNAdb. Available online: http://crdd.osdd.net/servers/virsirnadb (accessed on 26 May 2020).
- Thakur, N.; Quereshi, A.; Kumar, M. VIRsiRNAdb: A curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res. 2012, 40, D230–D236. [Google Scholar] [CrossRef] [Scilit]
- HIVsirDB. Available online: http://crdd.osdd.net/raghava/hivsir (accessed on 26 May 2020).
- Database of HIV inhibiting siRNAs. Available online: http://crdd.osdd.net/raghava/hivsir/hiv-esc-seq.php (accessed on 26 May 2020).
- Tyagi, A.; Ahmed, F.; Thakur, N.; Sharma, A.; Raghave, G.P.; Kumar, M. HIVsiRDB: A database of HIV inhibiting siRNAs. PLoS ONE 2011, 6, e25917. [Google Scholar] [CrossRef] [Scilit]
- Amarzguioui, M.; Prydz, H. An algorhitm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 2004, 316, 1050–1058. [Google Scholar] [CrossRef] [Scilit]
- Naito, Y.; Ui-Tei, K.; Nishikawa, T.; Takebe, Y.; Saigo, K. siVirus: Web-based anti-viral siRNA design software for highly divergent viral sequences. Nucleic Acids Res. 2006, 34, W448–W450. [Google Scholar] [CrossRef] [Scilit]
- Nur, S.M.; Hasan, A.; Al Amin, M.; Hossain, M.; Sharmin, T. Design of potential RNAi (miRNA and siRNA) molecules for middle east respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method. Interdiscip. Sci. 2015, 7, 257–265. [Google Scholar] [CrossRef] [PubMed]
- Gomez, J.; Nadal, A.; Sabariegos, R.; Beguiristain, N.; Martell, M.; Piron, M. Three properties of the hepatitis C virus RNA genome related to antiviral strategies based on RNA-therapeutics: Variability, structural conformation and tRNA mimicry. Curr. Pharm. Des. 2004, 10, 3741–3756. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Herrera-Carillo, E.; Liu, Y.P.; Brekhout, B. Improving miRNA expression cassettes in diverse virus vectors. Hum. Gene Ther. Meth. 2017, 28, 177–190. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Raouane, M.; Desmaele, D.; Urbinati, G.; Massaad-Massade, L.; Couvreur, P. Lipid conjugated oligonucleotides: A useful strategy for delivery. Bioconjug. Chem. 2012, 23, 1091–1104. [Google Scholar] [CrossRef] [Scilit]
- Layek, B.; Lipp, L.; Singh, J. Cell Penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid. Int. J. Mol. Sci. 2015, 16, 28912–28930. [Google Scholar] [CrossRef] [Scilit]
- O’Loughlin, A.J.; Mager, I.; de Jong, O.G.; Varela, M.A.; Schiffelers, R.M.; El Andaloussi, S.; Wood, M.J.A.; Vader, P. Functional delivery of lipid-conjugated siRNA by extracellular vesicles. Mol. Ther. 2017, 25, 1580–1587. [Google Scholar] [CrossRef] [Scilit]
- Wang, Y.; Chen, X.; Tian, B.; Liu, J.; Yang, L.; Zeng, L.; Chen, T.; Hong, A.; Wang, X. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics 2017, 7, 1360–1372. [Google Scholar] [CrossRef] [Scilit]
- Powell, D.; Chandra, S.; Dodson, K.; Shaheen, F.; Wiltz, K.; Ireland, S.; Syed, M.; Dash, S.; Wiese, T.; Mandal, T.; et al. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur. J. Pharm. Biopharm. 2017, 114, 108–118. [Google Scholar] [CrossRef] [Scilit]
- Brück, J.; Pascolo, S.; Fuchs, K.; Kellerer, C.; Glocova, I.; Geisel, J.; Dengler, K.; Yazdi, A.S.; Röcken, M.; Ghoreschi, K. Cholesterol modification of p40-specific small interfering RNA enables therapeutic targeting of dendritic cells. J. Immunol. 2015, 195, 2216–2223. [Google Scholar] [CrossRef] [Scilit]
- Wang, H.; Feng, Q.; Wei, L.; Zhuo, L.; Chen, H.; Diao, Y.; Tang, Y. Significant inhibition of Tembusu virus envelope and NS5 gene using an adenovirus-mediated short hairpin RNA delivery system. Infect. Genet. Evol. 2017, 54, 387–396. [Google Scholar] [CrossRef] [Scilit]
- Schaar, K.; Geisler, A.; Kraus, M.; Pinkert, S.; Pryshkliak, M.; Spencer, J.F.; Tollefson, A.E.; Ying, B.; Kurreck, J.; Wold, W.S.; et al. Anti-adenoviral artificial MicroRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian Hamsters. Mol. Ther. Nucleic Acids 2017, 8, 300–316. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Devroe, E.; Silver, P.A. Therapeutic potential of retroviral RNAi vectors. Expert Opin. Biol. Ther. 2004, 4, 319–321. [Google Scholar] [CrossRef] [PubMed]
- Westerhout, E.M.; Vink, M.; Hasnoot, P.C.J.; Das, A.T.; Berkhout, B. A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication. Mol. Ther. 2006, 14, 268–275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bastin, D.; Aitken, A.S.; Pelin, A.; Pikor, L.A.; Crupi, M.J.F.; Huh, M.S.; Bourgeois-Daigneault, M.C.; Bell, J.C.; Ilkow, C.S. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. J. Immunother. Cancer 2018, 6, 62. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ylosmaki, E.; Martikainen, M.; Hinkkanen, A.; Saksela, K. Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting. J. Virol. 2013, 87, 335–344. [Google Scholar] [CrossRef] [Scilit]
- Baltusnikas, J.; Satkauskas, S.; Lundstrom, K. Constructing RNA viruses for long-term transcriptional gene silencing. Trends Biotechnol. 2019, 37, 20–28. [Google Scholar] [CrossRef] [Scilit]
- Bagasra, O. RNAi as an antiviral therapy. Expert Opin. Biol. Ther. 2005, 5, 1463–1474. [Google Scholar] [CrossRef] [Scilit]
- Ibrisimovic, M.; Kneidinger, D.; Lion, T.; Klein, R. An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial miRNAs. Antivir. Res. 2013, 97, 10–23. [Google Scholar] [CrossRef] [Scilit]
- Mowa, M.B.; Crowther, C.; Ely, A.; Arbuthnot, P. Efficient silencing of hepatis B by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna 2012, 1, 19–25. [Google Scholar] [CrossRef] [Scilit]
- Mowa, M.B.; Crowther, C.; Ely, A.; Arbuthnot, P. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-mRs from a liver-specific promoter. Biomed Res. Int. 2014, 2014, 718743. [Google Scholar] [CrossRef] [Scilit]
- Chen, C.-C.; Sun, C.-P.; Ma, H.-I.; Fang, C.-C.; Wu, P.-Y.; Xiao, X.; Tao, M.-H. Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus Serotypes 7, 8, and 9. Mol. Ther. 2009, 17, 352–359. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, C.-C.; Chang, C.-M.; Sun, C.-P.; Yu, C.-P.; Wu, P.-Y.; Jeng, K.-S.; Hu, C.-P.; Chen, P.-J.; Wu, J.C.; Shih, C.-H.; et al. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther. 2012, 19, 25–33. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Maepa, M.B.; Ely, A.; Grayson, W.; Arbuthnot, P. Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs. Mol. Ther. Nucleic Acids 2017, 7, 190–199. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Macpherson, J.L.; Boyd, M.P.; Arndt, A.J.; Todd, A.V.; Fanning, G.C.; Ely, J.A.; Elliott, F.; Knop, A.; Raponi, M.; Murray, J.; et al. Long term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV infected patients. J. Gene Med. 2005, 7, 552–564. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Amado, R.G.; Mitsuyasu, R.T.; Rosenblatt, J.D.; Ngok, F.K.; Bakker, A.; Cole, S.; Chorn, N.; Lin, L.S.; Bristol, G.; Boyd, M.P.; et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a Phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. 2004, 15, 251–262. [Google Scholar] [CrossRef] [Scilit]
- Mitsuyasu, R.T.; Merigan, T.C.; Carr, A.; Zack, J.A.; Winters, M.A.; Workman, C.; Bloch, M.; Lalezari, J.; Becker, S.; Thornton, L.; et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34(+) cells. Nat. Med. 2009, 15, 285–292. [Google Scholar] [CrossRef] [Scilit]
- Kumar, M.; Follenzi, A.; Garforth, S.; Gupta, S. Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches. Antivir. Ther. 2012, 17, 519–528. [Google Scholar] [CrossRef] [Scilit]
- Li, M.J.; Kim, J.; Li, S.; Zaia, J.; Yee, J.-K.; Anderson, J.; Akkina, R.; Ross, J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 2005, 12, 900–909. [Google Scholar] [CrossRef] [Scilit]
- DiGiusto, D.L.; Krishnan, A.; Li, L.; Li, H.; Li, S.; Rao, A.; Mi, S.; Yam, P.; Stinson, S.; Kalos, M.; et al. RNA-based gene therapy for HIV with lentiviral vector modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010, 2, 36–43. [Google Scholar] [CrossRef] [Scilit]
- Herrera-Carrillo, E.; Berkhout, B. Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection. PLoS ONE 2017, 12, e0177935. [Google Scholar] [CrossRef] [Scilit]
- McCarthy, D.M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 2008, 16, 1648–1656. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mnyandu, N.; Arbuthnot, P.; Maepa, M.B. In vivo delivery of cassettes encoding anti-HBV primary microRNAs using an ancestral adeno-associated viral vector. Methods Mol. Biol. 2020, 2115, 171–183. [Google Scholar] [PubMed]
- Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D.; et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 2008, 118, 3143–3150. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yu, S.F.; von Ruden, T.; Kantoff, P.W.; Garber, C.; Seiberg, M.; Rüther, U.; Anderson, W.F.; Wagner, E.F.; Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 1986, 83, 3194–3198. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ter Brake, O.; Berkhout, B. Lentiviral vectors that carry anti-HIV shRNAs: Problems and solutions. J. Gene Med. 2007, 9, 743–750. [Google Scholar] [CrossRef] [Scilit]
- Kotsopoulou, E.; Kim, V.N.; Kingsman, A.J.; Kingsman, S.M.; Mitrophanous, K.A. A rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 2000, 74, 4839–4852. [Google Scholar] [CrossRef] [Scilit]
- Berkhout, B.; Liu, Y.P. Towards improved shRNA and miRNA reagents as inhibitors of HIV-1 replication. Future Microbiol. 2014, 9, 561–571. [Google Scholar] [CrossRef] [Scilit]
- Martikainen, M.; Niittykoski, M.; von und zu Frauenberg, M.; Immonen, A.; Koponen, S. MicroRNA-attenuated clone of virulent Semliki Forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma. J. Virol. 2015, 89, 10637–10647. [Google Scholar] [CrossRef] [Scilit]
- Ramachandran, M.; Yu, D.; Dyczynski, M.; Baskaran, S.; Zhang, L.; Lulla, A.; Lulla, V.; Saul, S.; Nelander, S.; Dimberg, A.; et al. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted Oncolytic Semliki forest virus. Clin. Cancer Res. 2017, 23, 1519–1530. [Google Scholar] [CrossRef] [Scilit]
- Kong, W.H.; Bae, K.H.; Jo, S.D.; Kim, J.S.; Park, T.G. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm. Res. 2012, 29, 362–374. [Google Scholar] [CrossRef] [Scilit]
- Saulnier, A.; Pelletier, I.; Labadie, K.; Colbère-Garapin, F. Complete cure of persistant virus infections by antiviral siRNAs. Mol. Ther. 2006, 13, 142–150. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thi, E.P.; Mire, C.E.; Lee, A.C.; Geisbert, J.B.; Ursic-Bedoya, R.; Agans, K.N.; Robbins, M.; Deer, D.J.; Cross, R.W.; Kondratowicz, A.S.; et al. siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J. Clin. Investig. 2017, 127, 4437–4448. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Villegas, P.M.; Ortega, E.; Villa-Tanaca, L.; Barron, B.L.; Torres-Flores, J. Inhibition of Dengue virus infection by small interfering RNAs that target highly conservative sequences in the NS4B or NS5 coding regions. Arch. Virol. 2018, 163, 1331–1335. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dash, P.K.; Tiwari, M.; Santhosh, S.R.; Parida, M.; Rao, P.V.L. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem. Biophys. Res. Commun. 2008, 376, 718–722. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Saha, A.; Bhagyawant, S.; Parida, M.; Dash, P.K. Vector-delivered artificial miRNA effectively inhibited replication of Chikungunya virus. Antivir. Res. 2016, 134, 42–49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ma, H.; Dallas, A.; Ilves, H.; Shorenstein, J.; MacLachlan, I.; Klumpp, K.; Johnston, B.H. Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers. Gastroenterology 2014, 146, 63–66. [Google Scholar] [CrossRef] [Scilit]
- Idrees, S.; Ashfaq, U.A. RNAi: Antiviral therapy against dengue virus. Asian Pac. J. Trop. Biomed. 2013, 3, 232–236. [Google Scholar] [CrossRef] [Scilit]
- Zhang, Y.; Li, T.; Fu, L.; Yu, C.; Li, Y.; Xu, X.; Wang, Y.; Ning, H.; Zhang, S.; Chen, W.; et al. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett. 2004, 560, 141–146. [Google Scholar] [CrossRef] [Scilit]
- Zheng, B.J.; Guan, Y.; Tang, Q.; Du, C.; Xie, F.Y.; He, M.L.; Chan, K.W.; Wong, K.L.; Lader, E.; Woodle, M.C.; et al. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir. Res. 2004, 9, 365–374. [Google Scholar]
- Li, B.-J.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F.Y.; Wei, Q.; Xu, J.; Liu, Y.; Zhen, B.-J.; Woodle, M.C.; et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaques. Nat. Med. 2005, 11, 944–951. [Google Scholar] [CrossRef] [Scilit]
- Lu, C.Y.; Huang, H.-Y.; Yang, T.H.; Chang, L.Y.; Lee, C.Y.; Huang, L.M. siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero cells. Eur. J. Clin. Microbiol. Infect. Dis. 2008, 27, 709–715. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Millet, J.K.; Nal, B. Investigation of the functional roles of host cell proteins involved in coronavirus infection using highly specific and scalable RNA interference (RNAi) approach. Methods Mol. Biol. 2015, 1282, 231–240. [Google Scholar] [PubMed]
- Sohrab, S.S.; El-Kafrawy, S.A.; Mirza, Z.; Kamal, M.A.; Azhar, E.I. Design and delivery of therapeutic siRNAs: Application of MERS-Coronavirus. Curr. Pharm. Des. 2018, 24, 62–77. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gu, W.Y.; Li, Y.; Liu, B.J.; Wang, J.; Yuan, G.F.; Chen, S.J.; Zuo, Y.Z.; Fan, J.H. Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells. Virus Genes 2019, 55, 795–801. [Google Scholar] [CrossRef] [Scilit]
- Li, K.; Li, H.; Bi, Z.; Song, D.; Zhang, F.; Lei, D.; Luo, S.; Li, Z.; Gong, W.; Huang, D.; et al. Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector. Antivir. Res. 2019, 166, 11–18. [Google Scholar] [CrossRef] [Scilit]
- Chen, W.; Feng, P.; Liu, K.; Wu, M.; Lin, H. Computational identification of small RNA targets in SARS-CoV-2. Virol. Sin. 2020, 1–3. [Google Scholar] [CrossRef] [Scilit]
- Zhao, W.M.; Song, S.H.; Chen, M.L.; Zou, D.; Ma, L.N.; Ma, Y.K.; Li, R.J.; Hao, L.L.; Li, C.P.; Tian, D.M.; et al. The 2019 novel coronavirus resource. Yi Chuan 2020, 42, 212–222. [Google Scholar]
- Taroncher-Oldenburg, G.; Marshall, A. Trends in biotech literature 2006. Nat. Biotechnol. 2007, 25, 961. [Google Scholar] [CrossRef] [Scilit]
- Seyhan, A.A.; Rya, T.E. RNAi screening for the discovery of novel modulators of human disease. Curr. Pharm. Biotechnol. 2010, 11, 735–756. [Google Scholar] [CrossRef] [Scilit]
- Houseley, J.; Tollervey, D. The many pathways of RNA degradation. Cell 2009, 136, 763–776. [Google Scholar] [CrossRef] [Scilit]
- Lundstrom, K. Latest development on RNA-based drugs and vaccines. Future Sci. OA 2018, 4, FSO300. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hadinoto, K.; Sundaresan, A.; Cheow, W.S. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. Eur. J. Pharm. Biopharm. 2013, 85, 427–443. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lundstrom, K. Self-amplifying RNA viruses as RNA vaccines. Int. J. Mol. Sci. 2020, 21, 5130. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tiemann, K.; Rosso, J.J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med. 2009, 1, 142–151. [Google Scholar] [CrossRef] [Scilit]
- Jackson, A.L.; Burchard, J.; Schelter, J.; Chau, B.N.; Cleary, M.; Lim, L.; Linsley, P.S. Widespread siRNA ‘off-target’ transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12, 1179–1187. [Google Scholar] [CrossRef] [Scilit]
- Grimm, D.; Streetz, K.L.; Jopling, C.L.; Storm, T.A.; Pandey, K.; Davis, C.R.; Marion, P.; Salazar, F.; Kay, M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441, 537–541. [Google Scholar] [CrossRef] [Scilit]
- Robbins, M.; Judge, A.; Ambegia, E.; Choi, C.; Yaworski, E.; Palmer, L.; McClintock, K.; Maclachlan, I. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. 2008, 19, 991–999. [Google Scholar] [CrossRef] [Scilit]
- Judge, A.; MacLachlan, I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 2008, 19, 111–124. [Google Scholar] [CrossRef] [Scilit]
- Kaiser, P.K.; Symons, R.C.A.; Shah, S.M.; Quinlan, E.J.; Tabandeb, H.; Do, D.V.; Reisen, G.; Lockridge, J.A.; Short, B.; Guerciolini, R.; et al. RNAi-based treatment for neurovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. 2010, 150, 33–39. [Google Scholar] [CrossRef] [Scilit]
- AMD Book. Available online: https://amdbook.org/content/agn-745-sirna-027-wet-amd-development-was-halted (accessed on 28 May 2020).
- Setten, R.L.; Rossi, J.J.; Han, S.-P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 2019, 18, 421–446. [Google Scholar] [CrossRef] [Scilit]
- Weng, Y.; Xiao, H.; Zhang, J.; Liang, X.-J.; Huang, Y. RNAi Therapeutic and Its Innovative Biotechnological Evolution. Biotechnol. Adv. 2019, 37, 801–825. [Google Scholar] [CrossRef] [Scilit] [PubMed]
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).